Published in Pediatr Rheumatol Online J on May 08, 2014
Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus. Arthritis Res Ther (2016) 0.79
C1q rs292001 polymorphism and C1q antibodies in juvenile lupus and their relation to lupus nephritis. Clin Exp Immunol (2015) 0.78
Network analysis and juvenile idiopathic arthritis (JIA): a new horizon for the understanding of disease pathogenesis and therapeutic target identification. Pediatr Rheumatol Online J (2016) 0.75
Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 88.48
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Exploring the new world of the genome with DNA microarrays. Nat Genet (1999) 19.05
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 11.05
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 8.14
Molecular characterisation of soft tissue tumours: a gene expression study. Lancet (2002) 7.05
The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med (2000) 5.74
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59
Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet (2000) 4.98
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet (2005) 4.80
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med (2005) 4.79
Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet (2007) 4.76
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 4.51
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 4.42
Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol (2006) 3.70
Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science (1982) 3.67
Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol (2001) 3.55
Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med (2007) 3.51
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med (2003) 3.50
Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med (2004) 3.34
Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet (2001) 3.21
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet (2009) 3.07
Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet (2007) 2.73
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet (2012) 2.63
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med (2006) 2.53
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol (2013) 2.36
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature (2010) 2.31
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2009) 2.31
Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum (2006) 2.27
Microarray analysis of interferon-regulated genes in SLE. Autoimmunity (2003) 2.24
Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun (2003) 2.23
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2012) 2.21
Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum (2009) 2.20
Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet (2011) 2.16
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2008) 2.08
Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol (1999) 2.03
C1q, autoimmunity and apoptosis. Immunobiology (2002) 1.94
Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol (2000) 1.88
Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int (1994) 1.88
Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet (2011) 1.84
Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest (2004) 1.82
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum (2011) 1.79
Complement in human diseases: Lessons from complement deficiencies. Mol Immunol (2009) 1.73
Genomic views of the immune system*. Annu Rev Immunol (2000) 1.60
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol (2004) 1.57
Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am (1991) 1.50
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.38
Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol (2009) 1.37
C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol (2010) 1.34
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol (2008) 1.29
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol (2003) 1.28
Role of neutrophils in the pathogenesis of experimental vasculitis. Am J Pathol (1996) 1.23
Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23
Role of neutrophil elastase in the development of renal necrotizing vasculitis. Clin Nephrol (1996) 1.14
Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus (2003) 1.13
The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol (2012) 1.12
Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev (2003) 1.09
Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 1.08
Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford) (2013) 1.05
Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem (1995) 1.05
Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol (2014) 1.04
Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transplant (2006) 1.01
Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J Immunol (2011) 0.97
Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet (2013) 0.96
Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther (2013) 0.94
Gene-expression profiling in rheumatic disease: tools and therapeutic potential. Nat Rev Rheumatol (2009) 0.89
The pitfalls in the development of biologic therapy. Nat Clin Pract Rheumatol (2007) 0.88
Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. J Rheumatol (2006) 0.86
Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol (2013) 0.83
Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) (2003) 0.80